高危低级别胶质瘤放疗与化疗的成本效益分析
本研究采用决策树联合三状态马尔可夫模型,评估高危低级别胶质瘤术后放疗联合丙卡巴肼、洛莫司汀、长春新碱(PCV)化疗与单纯放疗的成本效益。结果显示,联合治疗增量成本效益比为每获得1个质量调整生命年10186美元,在10万美元/质量调整生命年的支付意愿阈值下具有99.96%的概率为成本效益方案。
要点
- 高危低级别胶质瘤术后放疗联合PCV化疗较单纯放疗增量获益4.77个质量调整生命年。
- 联合治疗增量成本为48635美元,增量成本效益比为每质量调整生命年10186美元。
- 在10万美元/质量调整生命年阈值下,联合治疗为成本效益方案的概率为99.96%。
核心结论
- 在高危低级别胶质瘤患者中,放疗联合PCV化疗是一种成本效益治疗方案。
研究设计与样本
- 研究构建决策树并整合三状态马尔可夫模型,模拟高危低级别胶质瘤术后接受放疗与放疗联合PCV化疗的患者。
- 模型包含稳定、进展、死亡三种健康状态,生存和无进展生存按RTOG 9802结果以时间依赖转移概率建模。
- 健康效用值和医疗成本来自文献及国家登记数据库,分析采用卫生保健视角,并进行确定性和概率敏感性分析。
主要发现
- 模型结果与临床数据一致,显示放疗联合PCV较单纯放疗具有预期获益。
- 放疗联合PCV组质量调整生命年为9.94,单纯放疗组为5.17,增量获益4.77个质量调整生命年。
- 放疗联合PCV组成本为188234美元,单纯放疗组为139598美元,增量成本48635美元。
- 增量成本效益比为每获得1个质量调整生命年10186美元。
- 概率敏感性分析显示,在模型参数分布内,以每质量调整生命年100000美元为支付意愿阈值,放疗联合PCV具有99.96%的概率为成本效益方案。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The addition of procarbazine, lomustine, vincristine (PCV) chemotherapy to radiotherapy (RT) for patients with high-risk (≥40 y old or subtotally resected) low-grade glioma (LGG) results in an absolute median survival benefit of over 5 years. We evaluated the cost-effectiveness of this treatment strategy. METHODS: A decision tree with an integrated 3-state Markov model was created to follow patients with high-risk LGG after surgery treated with RT versus RT+PCV. Patients existed in one of 3 health states: stable, progressive, or dead. Survival and freedom from progression were modeled to reflect the results of RTOG 9802 using time-dependent transition probabilities. Health utility values and costs of care were derived from the literature and national registry databases. Analysis was conducted from the health care perspective. Deterministic and probabilistic sensitivity analysis explored uncertainty in model parameters. RESULTS: Modeled outcomes demonstrated agreement with clinical data in expected benefit of addition of PCV to RT. The addition of PCV to RT yielded an incremental benefit of 4.77 quality-adjusted life-years (QALYs) (9.94 for RT+PCV vs 5.17 for RT alone) at an incremental cost of $48635 ($188234 for RT+PCV vs $139598 for RT alone), resulting in an incremental cost-effectiveness ratio of $10186 per QALY gained. Probabilistic sensitivity analysis demonstrates that within modeled distributions of parameters, RT+PCV has 99.96% probability of being cost-effectiveness at a willingness-to-pay threshold of $100000 per QALY. CONCLUSION: The addition of PCV to RT is a cost-effective treatment strategy for patients with high-risk LGG.
引用
- Qian Y, Maruyama S, Kim H, et al. Cost-effectiveness of radiation and chemotherapy for high-risk low-grade glioma. Neuro Oncol. 2017. PMID: 28666368. doi:10.1093/neuonc/nox121
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。